Onyx Pharmaceuticals Announces Data Presentations Highlighting Carfilzomib and ONX 0803 at 51st American Society of Hematology A
November 10 2009 - 3:00PM
PR Newswire (US)
EMERYVILLE, Calif., Nov. 10 /PRNewswire-FirstCall/ -- Onyx
Pharmaceuticals, Inc. (NASDAQ:ONXX) today announced nearly 20
presentations evaluating carfilzomib and ONX 0803 (SB 1518) in
hematological cancers at the 51st American Society of Hematology
(ASH) Annual Meeting December 5-8, 2009 in New Orleans, LA. Among
the data presentations are four oral and seven poster presentations
highlighting data from the carfilzomib development program in
patients with relapsed and refractory multiple myeloma. Onyx
Pharmaceuticals has previously announced its intent to acquire
Proteolix Inc. Until the transaction closes, carfilzomib remains an
asset of Proteolix Inc. "The breadth of data being presented at ASH
showcases our growing, diverse oncology pipeline, which we expect
to fuel the future growth of Onyx, and positions the company to
bring multiple, new treatment options to cancer patients," said
Todd Yancey, vice president clinical development at Onyx. "Despite
recent treatment advances, multiple myeloma remains a disease with
poor long-term survival and there is a tremendous need for new
therapies. Assuming the Proteolix transaction closes, our
development plan will include evaluating carfilzomib, a
next-generation selective proteasome inhibitor, across multiple
lines of therapy, as a single agent and in combination with other
therapies for the treatment of multiple myeloma." Carfilzomib data
highlights include: Multiple Myeloma -- Updated Results of
Bortezomib-Naive Patients in PX-171-004, an Ongoing, Open-Label,
Phase II Trial of Single-Agent Carfilzomib (CFZ) in Patients with
Relapsed or Refractory Myeloma (MM) -- Dr. Michael Wang, University
of Texas MD Anderson Cancer Center -- Monday, December 7, 2009,
7:15 - 7:30 a.m., La Nouvelle Ballroom AB -- Oral Session: Myeloma
- Therapy, Excluding Transplantation I -- Abstract # 302 --
PX-171-004, an Ongoing Open-Label, Phase II Study of Single-Agent
Carfilzomib (CFZ) in Patients with Relapsed or Refractory Myeloma
(MM); Updated Results from the Bortezomib-Treated Cohort -- Dr.
David Siegel, Hackensack University Medical Center -- Monday,
December 7, 2009, 7:30 - 7:45 a.m., La Nouvelle Ballroom AB -- Oral
Session: Myeloma - Therapy, Excluding Transplantation I -- Abstract
# 303 -- Phase Ib Multicenter Dose Escalation Study of Carfilzomib
Plus Lenalidomide and Low Dose Dexamethasone (CRd) in Relapsed and
Refractory Multiple Myeloma (MM) -- Dr. Ruben Niesvizky, New York
Presbyterian Hospital-Cornell Medical Center -- Monday, December 7,
2009, 7:45 - 8:00 a.m., La Nouvelle Ballroom AB -- Oral Session:
Myeloma - Therapy, Excluding Transplantation I -- Abstract # 304 --
Carfilzomib (CFZ), a Novel Proteasome Inhibitor for Relapsed or
Refractory Multiple Myeloma is Associated with Minimal Peripheral
Neuropathic Effects -- Dr. Ravi Vij, Washington University School
of Medicine -- Monday, December 7, 2009, 11:15 - 11:30 a.m., Hall F
-- Oral Session: Myeloma -Therapy Excluding Transplantation: New
Drugs in Multiple Myeloma and Amyloidosis -- Abstract # 430 ONX
0803 (SB1518) data highlights include: Lymphoma -- Phase I Study of
the Novel Oral JAK-2 Inhibitor SB1518 in Patients with Relapsed
Lymphoma: Evidence of Clinical and Biological Activity -- Dr. Anas
Younes, University of Texas MD Anderson Cancer Center -- Monday,
December 7, 2009, 4:00 - 4:15 p.m., R02-R05 -- Oral Session:
Lymphoma: Therapy with Biologic Agents, excluding Pre-Clinical
Models: New Targets in the Treatment of Lymphomas -- Abstract # 588
About Onyx Pharmaceuticals, Inc. Onyx Pharmaceuticals, Inc. is a
biopharmaceutical company committed to improving the lives of
people with cancer. The company, in collaboration with Bayer
HealthCare Pharmaceuticals, Inc., is developing and marketing
Nexavar®, a small molecule drug. Nexavar is currently approved for
the treatment of liver cancer and advanced kidney cancer.
Additionally, Nexavar is being investigated in several ongoing
trials in a variety of tumor types. For more information about
Onyx, visit the company's website at http://www.onyx-pharm.com/.
Forward Looking Statements This news release contains
"forward-looking statements" of Onyx within the meaning of the
federal securities laws. These forward-looking statements include
without limitation, statements regarding the consummation and
anticipated benefits of the proposed acquisition of Proteolix and
the timing, progress and results of the clinical development,
safety, regulatory processes, commercialization efforts or
commercial potential of carfilzomib. These statements are subject
to risks and uncertainties that could cause actual results and
events to differ materially from those anticipated, including risks
related to the ability of each company to meet the conditions
necessary to close this transaction, the risk that Proteolix's
operations will not be integrated successfully into Onyx's, the
risk that Onyx may not realize the anticipated benefits of the
acquisition and risks related to the development and
commercialization of pharmaceutical products. Any statements
contained in this press release that are not statements of
historical fact may be deemed to be forward-looking statements.
Reference should be made to Onyx's Annual Report on Form 10-K for
the year ended December 31, 2008, filed with the Securities and
Exchange Commission under the heading "Risk Factors" and Onyx's
Quarterly Reports on Form 10-Q for a more detailed description of
such factors. Readers are cautioned not to place undue reliance on
these forward-looking statements that speak only as of the date of
this release. Onyx undertakes no obligation to update publicly any
forward-looking statements to reflect new information, events, or
circumstances after the date of this release except as required by
law. Nexavar® (sorafenib) tablets is a registered trademark of
Bayer HealthCare Pharmaceuticals. DATASOURCE: Onyx Pharmaceuticals,
Inc. CONTACT: Investors, Julie Wood, +1-510-597-6505, or Media,
Lori Murray, +1-510-597-6394, both of Onyx Pharmaceuticals; or
Danielle Bertrand of WeissComm Partners, +1-415-946-1056, for Onyx
Pharmaceuticals Web Site: http://www.onyx-pharm.com/
Copyright
Onyx Pharmaceuticals, Inc. (MM) (NASDAQ:ONXX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Onyx Pharmaceuticals, Inc. (MM) (NASDAQ:ONXX)
Historical Stock Chart
From Jul 2023 to Jul 2024